There are 2789 resources available
537P - Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care
Presenter: Stefanie Krens
Session: ePoster Display
539P - Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Presenter: Jianming Xu
Session: ePoster Display
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display
541P - Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Presenter: Maen Hussein
Session: ePoster Display
542P - Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
Presenter: Manish Patel
Session: ePoster Display
543P - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Presenter: Mark Lythgoe
Session: ePoster Display
583P - Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
Presenter: Vincenza Conteduca
Session: ePoster Display
584P - Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Stephane Oudard
Session: ePoster Display
585P - Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Cora Sternberg
Session: ePoster Display